TransMedics Group, Inc.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company focused on organ transplantation for patients with end-stage organ failure. Its Organ Care System (OCS) is a portable, warm-perfusion platform that maintains donor hearts, lungs and livers in a functioning state outside the body, enabling organ… From the company’s description.
Over the twelve months to Sep 30, 2026, TransMedics Group, Inc. reported revenue of $727.65M, up 28.5% from a year earlier, and net income of $144.45M. Its operating margin was 11.9%, and operations generated $112.36M in cash. In fiscal 2025, it reported revenue of $605.49M, up 37.1% from fiscal 2024, and net income of $190.29M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TransMedics Group, Inc. does
In the company’s own words
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company focused on organ transplantation for patients with end-stage organ failure. Its Organ Care System (OCS) is a portable, warm-perfusion platform that maintains donor hearts, lungs and livers in a functioning state outside the body, enabling organ monitoring and assessment during transport; products include OCS Heart, OCS Lung and OCS Liver. The company also provides its National OCS Program (NOP), an outsourced service combining organ procurement, OCS perfusion management and transplant logistics, including air and ground transportation, for U.S. transplant centers. It sells through the NOP and a direct acquisition model in which centers purchase equipment and disposables and train their own teams. Revenue is primarily from single-use, organ-specific disposable sets and NOP services. TransMedics acquired Summit Aviation in 2023, adding aircraft transportation to its logistics services, and has acquired 22 fixed-wing aircraft. It reports one business, with total revenue of $605.5 million in fiscal 2025 and 898 employees worldwide as of December 31, 2025. Its website is www.transmedics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- ANDOVER, MA
- Fiscal year end
- December
- CIK
- 1756262
- SIC
- 3845
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TransMedics Group, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TransMedics Group, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
TransMedics Group, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of TransMedics Group, Inc.’s debt, $35.26M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.50%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TransMedics Group, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TransMedics Group, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TransMedics Group, Inc.'s last four quarterly filings that the numbers alone won't show?”